Simple Summary Tumor hypoxia remains a significant problem in the effective treatment of
most cancers. Tumor cells within hypoxic niches tend to be largely resistant to most …

Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …

Clear cell renal cell carcinoma (ccRCC) is a type of kidney cancer that arises from the cells
lining the tubes of the kidney. The tumor immune microenvironment (TIME) of ccRCC is a …

Abstract Treatment for renal cell carcinoma (RCC) has improved dramatically over the last
decade, shifting from high-dose cytokine therapy in combination with surgical resection of …

Simple Summary Carbonic anhydrase IX (CAIX) has been explored for a long time as a
therapeutic target in the fight against clear cell renal cell carcinoma and several hypoxic …

Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer
immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical …

The complete regression of clear cell renal cell carcinoma (ccRCC) obtained pre-clinically
with anti-carbonic anhydrase IX (CAIX) G36 chimeric antigen receptor (CAR) T cells in …

Since the first studies, the mouse models have provided crucial support for the most
important discoveries on NK cells, on their development, function, and circulation within …

Carbonic anhydrases (CAs), are metallo-enzymes implicated in several pathophysiological
processes where tissue pH regulation is required. CA IX is a tumor-associated CA isoform …

One of the major hurdles that has hindered the success of chimeric antigen receptor (CAR) T
cell therapies against solid tumors is on-target off-tumor (OTOT) toxicity due to sharing of the …